To live up to the challenge and address the chronic diseases afflicting the population, biotech in China is committed for the long haul - R&D outcomes remain fickle and international license agreements get caught up in geopolitics
With a small number of facilities in the US, the logistics of individual treatment – and their length – are likely to limit patient access and the pricing structures raise issues with vast implications for insurers and patients alike
The foundations of cancer treatment have been surgery, chemotherapy, radiation therapy and targeted therapies homing in on specific molecular changes seen primarily in cancer cells
